Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | FPR2 | P25090 | 2/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73700 | 1.00 | ACE (0.51) | ACENPSR1FPR2ECE1PTPN1 | |
| SCHEMBL8703498 | 0.88 | ACE (0.52) | ACENPSR1FPR2ECE1PTPN1 | |
| SCHEMBL6254380 | 0.88 | PTPN1 (0.56) | ACEPTPN1 | |
| SCHEMBL71782 | 0.83 | ACE (0.56) | ACENPSR1FPR2ECE1L3MBTL1 | |
| SCHEMBL71781 | 0.83 | ACE (0.56) | ACENPSR1FPR2ECE1L3MBTL1 | |
| SCHEMBL933401 | 0.83 | ACE (0.56) | ACENPSR1FPR2ECE1L3MBTL1 | |
| SCHEMBL7322706 | 0.81 | MME (0.59) | ACEMMEACE2CPA1 | |
| SCHEMBL7348036 | 0.81 | MME (0.59) | ACEMMEACE2CPA1 | |
| SCHEMBL9223334 | 0.80 | NPSR1 (0.55) | ACENPSR1L3MBTL1MMEALDH1A1 | |
| SCHEMBL2622217 | 0.80 | NPSR1 (0.55) | ACENPSR1L3MBTL1MMEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028630-A1 | HYBRID OLIGONUCLEOTIDES | ENTRADA THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20240245790-A1 | CYCLIC CELL PENETRATING PEPTIDES | ENTRADA THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| US-20210196842-A1 | SITE-SPECIFIC RADIOFLUORINATION OF PEPTIDES WITH 8-[18F]-FLUOROOCTANOIC ACID CATALYZED BY LIPOIC ACID LIGASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-01 | — | — | US | disclosed |
| WO-2017095806-A1 | SITE-SPECIFIC RADIOFLUORINATION OF PEPTIDES WITH 8-[18F]-FLUOROOCTANOIC ACID CATALYZED BY LIPOIC ACID LIGASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-08 | — | — | WO | disclosed |
| US-9399653-B2 | Methods and systems for preparing irreversible inhibitors of protein tyrosine phosphatases | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2016-07-26 | — | — | US | disclosed |
| EP-2267029-B1 | Methods and compositions for treatment of inflammatory disease using Cadherin-11 modulating agents | BRIGHAM & WOMENS HOSPITAL (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9284541-B2 | Methods and compositions for protein labeling using lipoic acid ligases | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150125904-A1 | PROBE INCORPORATION MEDIATED BY ENZYMES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-05-07 | — | — | US | disclosed |
| US-8871456-B2 | Probe incorporation mediated by enzymes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-10-28 | — | — | US | disclosed |
| WO-2013148189-A1 | PROBE INCORPORATION MEDIATED BY ENZYMES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-03 | — | — | WO | disclosed |
| WO-2001017557-A9 | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASE USING CADHERIN-11 MODULATING AGENTS | BRIGHAM & WOMENS HOSPITAL (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1207905-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASE USING CADHERIN-11 MODULATING AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2002036142-A2 | COMPOSITIONS FOR INHIBITING GRB7 | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2002-05-10 | — | — | WO | disclosed |
| US-20020055488-A1 | Prevention and treatment of streptococcal and staphylococcal infection | BRIGHAM AND WOMEN'S HOSPITAL, INC., THE | 2002-05-09 | — | — | US | disclosed |
| WO-2002024223-A2 | PREVENTION AND TREATMENT OF STREPTOCOCCAL AND STAPHYLOCOCCAL INFECTION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-1140980-A1 | PSEUDOPEPTIDE COMPOUNDS HAVING AN INHIBITING ACTIVITY WITH RESPECT TO PATHS ACTIVATED BY PROTEINS WITH ACTIVE TYROSINE KINASE ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001017557-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASE USING CADHERIN-11 MODULATING AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000039153-A1 | PSEUDOPEPTIDE COMPOUNDS HAVING AN INHIBITING ACTIVITY WITH RESPECT TO PATHS ACTIVATED BY PROTEINS WITH ACTIVE TYROSINE KINASE ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM (FR) | 2000-07-06 | — | — | WO | disclosed |
| US-5770620-A | ENZYME INHIBITOR AS IMMUNOMODULATORS | ONTOGEN CORPORATION (US) | 1998-06-23 | — | — | US | disclosed |
| WO-1997043301-A2 | IDENTIFICATION OF MEMBERS OF COMBINATORIAL LIBRARIES BY MASS SPECTROMETRY | NOVARTIS AG (CH) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028630-A1 | HYBRID OLIGONUCLEOTIDES | RNGTT, BCDIN3D, RNMT | ACE 3520/4885NPSR1 2377/4885FPR2 2989/4885 |
| US-20240245790-A1 | CYCLIC CELL PENETRATING PEPTIDES | SLC47A1, SLC47A2, VIP | ACE 4080/4885NPSR1 548/4885FPR2 487/4885 |
| US-20210196842-A1 | SITE-SPECIFIC RADIOFLUORINATION OF PEPTIDES WITH 8-[18F]-FLUOROOCTANOIC ACID CATALYZED BY LIPOIC ACID LIGASE | DLAT, FABP7, ACSL1 | ACE 1829/4885NPSR1 3699/4885FPR2 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.